Bavarian Nordic Completes Share Buy-Back Program
The company Bavarian Nordic A/S has successfully completed its recent share buy-back program. This initiative was originally announced in early January and has met its intended target of approximately DKK 150 million. The shares repurchased will be held as treasury stock and are aimed at optimizing the capital structure as well as fulfilling the long-term obligations related to the company’s share-based incentive programs for both the Board of Directors and Executive Management.
Details of the Share Buy-Back Program
In total, Bavarian Nordic repurchased 760,275 shares under this program. These transactions are in compliance with the existing regulations on market conduct established by the European Parliament. This ensures transparency and regulatory adherence throughout the share repurchase process.
Transaction Summary
The buy-back program involved multiple transactions, which demonstrate the commitment of Bavarian Nordic to its financial strategy. A detailed summary of the transactions conducted includes:
- Accumulated until recent transactions: 588,000 shares, average purchase price of DKK 197.87, transaction value of DKK 116,344,980.
- Recent transactions:
- January 27: 60,000 shares at DKK 192.51, total value DKK 11,550,600.
- January 28: 42,000 shares at DKK 194.97, total value DKK 8,188,740.
- January 29: 40,000 shares at DKK 197.15, total value DKK 7,886,000.
- January 30: 19,000 shares at DKK 197.99, total value DKK 3,761,810.
- January 31: 11,275 shares at DKK 201.09, total value DKK 2,267,290.
Following the completion of these transactions, Bavarian Nordic now holds a total of 1,044,510 treasury shares, which represent approximately 1.32% of the company’s overall share capital.
About Bavarian Nordic
Bavarian Nordic is renowned as a global vaccine company dedicated to improving public health through innovative vaccine solutions. The company serves as a preferred supplier of vaccines for mpox and smallpox to various governments, thereby enhancing overall public health preparedness. In addition to its significant role in infectious disease prevention, Bavarian Nordic also boasts a promising portfolio of travel vaccines.
Company Contact Information
For investor inquiries, you can reach Rolf Sass Sørensen, Vice President of Investor Relations for Europe at rss@bavarian-nordic.com, or by calling +45 61 77 47 43. In the U.S., contact Graham Morrell at Paddock Circle Advisors via graham@paddockcircle.com, Tel: +1 781 686 9600.
Media Inquiries
For media-related queries, Nicole Seroff, Vice President of Corporate Communications, can be reached at nise@bavarian-nordic.com, or by phone at +45 53 88 06 03.
Frequently Asked Questions
What prompted the share buy-back program by Bavarian Nordic?
The program was initiated to optimize the company's capital structure and support long-term incentive plans for the leadership team.
How much did Bavarian Nordic spend on the buy-back program?
The total amount spent on the share repurchases was approximately DKK 150 million.
What percentage of shares does Bavarian Nordic hold as treasury stock now?
Currently, Bavarian Nordic holds 1,044,510 treasury shares, which account for around 1.32% of its total share capital.
Where can I find more information about Bavarian Nordic?
More details about the company's operations and innovation in vaccines can be found on their official website.
Who can I contact for investor relations inquiries?
Investor inquiries can be directed to Rolf Sass Sørensen at rss@bavarian-nordic.com or through the provided phone number.
